PBH earnings analysis
What we found in PBH's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Prestige Consumer Healthcare Inc. reported total revenues of $1.088 billion for fiscal 2026, a decline of 4.3% compared to the previous year, driven primarily by drops in the Eye & Ear Care segment. Gross profit margins decreased to 54.7%, influenced by rising costs and supply chain challenges. The firm has focused on acquisitions, expanding its product portfolio, including the recent purchase of Pillar5. Notably, the company recorded a $10.3 million write-off related to a supplier loan during the year, indicating ongoing financial pressures.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Total Revenue Decline
- Revenues decreased by $49.1 million, or 4.3%, to $1.088 billion for fiscal 2026.
- Gross Profit Margin Decline
- Gross profit margin fell to 54.7% from 55.8%, indicating reduced profitability.
- Free Cash Flow Generation
- Free cash flow for 2026 was $257.6 million, an increase of $6.1 million from the previous year.
- Acquisition Strategy
- Acquired Pillar5 for $52.8 million, enhancing product offerings in the eye care segment.
- Cost Management Efforts
- Management is actively pursuing cost management strategies due to inflation and supply chain issues.
- Share Buyback Program
- Total share repurchased in fiscal 2026 was $162 million, reflecting commitment to returning value to shareholders.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Supplier Loan Write-off
- Wrote off $10.3 million related to a supplier loan, signaling financial distress in supply chain.
- Dependency on Key Retailers
- Walmart and Amazon collectively accounted for approximately 35% of revenues, heightening revenue risk if lost.
- Supply Chain Disruptions
- Continued supply chain challenges, especially in eye care products, expected to impact sales and customer relationships.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $3.91
- Gross margin
- 54.7%
- Operating margin
- 28.4%
- Segment
- North American OTC Healthcare
- Segment
- International OTC Healthcare
What they said about what is next.
No explicit numeric guidance provided; annual outlook deferred to earnings press release/call.
The filing reads worse than the one before it.
What came before.
- 10-Q · February 5, 2026
- Prestige Consumer Healthcare Inc. reported mixed results for Q3 2026, with revenues declining 2.4% to $283.4 million compared to Q3 2025, while diluted EPS was slightly below estimates at $1.14. Despite ongoing…
- 10-Q · November 6, 2025
- PBH reported Q2 2025 results with revenues of $274.1 million, down 3.4% from the prior year, and EPS of $1.07, exceeding estimates by 9.2%. The North American OTC Healthcare segment experienced a notable decline due to…
- 10-Q · August 7, 2025
- Prestige Consumer Healthcare Inc. reported lower revenues of $249.5 million for Q1 2026, down 6.6% from Q1 2025, with diluted EPS of $0.95, missing estimates by $0.05. Despite challenges in the North American OTC…
- 10-K · May 9, 2025
- Prestige Consumer Healthcare reported a modest revenue increase of $12.4 million to $1.138 billion for fiscal 2025, with net income climbing to $214.6 million. The company faced challenges in product supply and…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing PBH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever